AttributesValues
Author
Bibliographic Citation
  • Reck M., Ciuleanu T.-E., Cobo M., Schenker M., Zurawski B., Menezes J., Richardet E., Bennouna J., Felip E., Juan-Vidal O., Alexandru A., Sakai H., Lingua A., Reyes F., Souquet P.-J., de Marchi P., Martin C., Pérol M., Scherpereel A., Lu S., Paz-Ares L., Carbone D.P., Memaj A., Marimuthu S., Zhang X., Tran P., John T. . First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update . ESMO Open, 2021, 6 (5), pp.100273 . ⟨10.1016/j.esmoop.2021.100273⟩
  • Reck M., Ciuleanu T.-E., Cobo M., Schenker M., Zurawski B., Menezes J., Richardet E., Bennouna J., Felip E., Juan-Vidal O., Alexandru A., Sakai H., Lingua A., Reyes F., Souquet P.-J., de Marchi P., Martin C., Pérol M., Scherpereel A., Lu S., Paz-Ares L., Carbone D.P., Memaj A., Marimuthu S., Zhang X., Tran P., John T.. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
Title
  • First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
dc:date
  • 2021
Digital Object Identifier (DOI)
  • 10.1016/j.esmoop.2021.100273
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software